Show simple item record

dc.contributor.authorBjørnestad, Espen Øglænd
dc.contributor.authorDhar, Indu
dc.contributor.authorSvingen, Gard Frodahl Tveitevåg
dc.contributor.authorPedersen, Eva Kristine Ringdal
dc.contributor.authorØrn, Stein
dc.contributor.authorSvenningsson, Mads Malm
dc.contributor.authorTell, Grethe Seppola
dc.contributor.authorUeland, Per Magne
dc.contributor.authorSulo, Gerhard
dc.contributor.authorLaaksonen, Reijo
dc.contributor.authorNygård, Ottar Kjell
dc.date.accessioned2022-11-15T14:40:09Z
dc.date.available2022-11-15T14:40:09Z
dc.date.created2022-08-11T19:29:41Z
dc.date.issued2022
dc.identifier.issn0954-6820
dc.identifier.urihttps://hdl.handle.net/11250/3031980
dc.description.abstractBackground Trimethylamine N-oxide (TMAO) is an amine oxide generated by gut microbial metabolism. TMAO may contribute to atherothrombosis and systemic inflammation. However, the prognostic value of circulating TMAO for risk stratification is uncertain. Methods We assessed prospective relationships of plasma TMAO with long-term risk of all-cause, cardiovascular (CV), and non-CV mortality in the Western Norway Coronary Angiography Cohort (WECAC; 4132 patients with suspected coronary artery disease) and the Hordaland Health Study (HUSK; 6393 community-based subjects). Risk associations were examined using Cox regression analyses. Results Mean follow-up was 9.8 and 10.5 years in WECAC and HUSK, respectively. Following adjustments for established CV risk factors and indices of renal function in WECAC, the hazard ratios (HRs) (95% confidence intervals [CIs]) per one standard deviation increase in log-transformed plasma TMAO were 1.04 (0.97–1.12), 1.06 (0.95–1.18), and 1.03 (0.93–1.13) for all-cause, CV, and non-CV mortality, respectively. Essentially similar results were obtained in patients with angiographically significant coronary artery disease and patients with reduced left ventricular ejection fraction. Corresponding HRs (95% CIs) in the HUSK cohort were 1.03 (0.96–1.10), 1.01 (0.89–1.13), and 1.03 (0.95–1.12) for all-cause-, CV, and non-CV mortality, respectively. Conclusions Circulating TMAO did not predict long-term all-cause, CV, or non-CV mortality in patients with coronary heart disease or in community-based adults. This large study does not support a role of TMAO for patient risk stratification in primary or secondary prevention.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCirculating trimethylamine N-oxide levels do not predict 10-year survival in patients with or without coronary heart diseaseen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1111/joim.13550
dc.identifier.cristin2042547
dc.source.journalJournal of Internal Medicineen_US
dc.identifier.citationJournal of Internal Medicine. 2022.en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal